Morgan Stanley Reiterates Equalweight Rating on Solventum (SOLV)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Wall St falls as Trump's Iran remarks rattle investors; Broadcom gains
- Oil prices jump 7% as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
BTIG Starts Solventum (SOLV) at Neutral
September 5, 2024 5:40 AM EDTBTIG analyst Ryan Zimmerman initiates coverage on Solventum (NYSE: SOLV) with a Neutral rating.
The analyst comments "Solventum was spun out of 3M (MMM, Not Rated) in April 2024, creating a global healthcare company that operates in a variety of medical technology segments including Medical/Surgical, Dental, Health Information Systems, and Purification & Filtration with global sales of $8.2B and total addressable markets of $93B+. Historically the business segments within MMM underperformed and... More
